Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06035120 · ClinicalTrials.gov registry record · NA

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

A NA study of Emphysema or COPD and Emphysema, Pulmonary, sponsored by Pulmonx Corporation.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
20
Study locations

NCT06035120: Recruiting NA study of Emphysema or COPD and Emphysema, Pulmonary, sponsored by Pulmonx Corporation.

NCT06035120 is a NA study of Emphysema or COPD and Emphysema, Pulmonary that is actively recruiting participants, run by Pulmonx Corporation. The registered enrollment target is 200 participants, above the 46-participant average among 7 other Emphysema or COPD trials with a reported enrollment target (335% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06035120, a NA study of Emphysema or COPD and Emphysema, Pulmonary, is actively recruiting participants, sponsored by Pulmonx Corporation.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement of Zephyr Valve in the target lobe for bronchoscopic lung volume reduction (BLVR) and be followed for 24 months.

Primary Outcome

The percentage of study subjects that successfully convert from a positive collateral ventilation status (CV+) in the treated lobe to having little to no collateral ventilation (CV-) by Chartis.

Interventions

  • DEVICE AeriSeal System

Study Locations (20)

Pennsylvania

  • Penn Medicine - Philadelphia
  • Temple University - Philadelphia
  • Allegheny General Hospital - Pittsburgh
  • University of Pittsburgh Medical Center (UPMC) - Pittsburgh

Illinois

  • Northwestern University - Chicago
  • University of Chicago Medical Center - Chicago
  • OSF Saint Francis Medical Center - Peoria

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Brigham Lung Center - Boston

Australia

  • Royal Adelaide Hospital - Adelaide
  • Wesley Hospital - Brisbane

Arizona

  • Banner University Medical Center - Phoenix

Connecticut

  • Saint Francis Hospital and Medical Center (Trinity Health of New England) - Hartford

Florida

  • Orlando Health - Orlando

Michigan

  • Henry Ford Hospital - Detroit

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-02-22
Est. Completion 2028-03-31
Phase NA
Pulmonx Corporation

3 total trials

What NCT06035120 shows while recruiting

NCT06035120 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 46-participant average among 7 other Emphysema or COPD trials with a reported enrollment target (335% higher).

The record links to 2 conditions, with Emphysema or COPD appearing as the primary indexed condition, and to 1 intervention - of which AeriSeal System is the first listed.

NCT06035120 names 20 study sites across 13 states, led by Pennsylvania, Illinois, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06035120 about?

NCT06035120 is a clinical study titled "An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema". This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Charti...

What is the current status of trial NCT06035120?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-02-22. Estimated completion is 2028-03-31.

What conditions does trial NCT06035120 study?

This clinical trial studies the following conditions: Emphysema or COPD, Emphysema, Pulmonary.

What interventions are being tested in trial NCT06035120?

The interventions under investigation include: AeriSeal System (DEVICE).

Who is sponsoring clinical trial NCT06035120?

This trial is sponsored by Pulmonx Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06035120 being conducted?

This trial has 20 study locations across Arizona, Connecticut, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Emphysema or COPD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06035120, the US trial registry maintained by the National Library of Medicine. NCT06035120 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.